



SUVEN Life Sciences Ltd

Communication to investors **September 2018**

14-Nov-18

2018-19 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	Q2-FY19 vs Q2-FY18	FY 2018-19 YoY (6 months)
Growth in revenue	-14.18%	14.41%
Growth in PAT	-43.45%	-7.44%
Growth in EBIDTA	-38.16%	-3.64%
Growth in Pre-R&D EBIDTA	-29.78%	-2.31%
Increase in R&D Costs	6.23%	2.54%
R&D to sales	8.00%	9.59%







MAJOR PROFITABILITY RATIOS

	Q2 Sep 19	HY Sep 19
PAT to Income	18.67%	19.17%
EBIDTA to Income	32.26%	32.90%
Cash Flow to Income	24.45%	22.91%
Pre-R&D EBITDA to Income	45.15%	42.49%




Q2 to Q1 COMPARISON





REVENUE COMPARISON




14-Nov-18

2018-19 Q2 results



PAT COMPARISON




14-Nov-18

2018-19 Q2 results



EBIDTA COMPARISON




2018-19 Q2 results

14-Nov-18



R & D – EXPENDITURE




14-Nov-18

2018-19 Q2 results



PRE-R&D EBIDTA




14-Nov-18

2018-19 Q2 results



PRE-R&D CASHFLOW



14-Nov-18

2018-19 Q2 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2018-19 Q2	2018-19 Q1	Growth %	2017-18 Q2	Growth %	2018-19 HY	2017-18 HY	Growth %
Income	961.08	1,997.90	-51.90%	1,119.91	-14.18%	2,958.98	2,586.33	14.41%
Pre-R&D EBITDA	433.88	823.47	-47.31%	617.89	-29.78%	1,257.36	1,287.11	-2.31%
Pre-R&D EBITDA Margin	45.15%	41.22%		55.17%		42.49%	49.77%	
EBITDA	310.01	663.59	-53.28%	501.28	-38.16%	973.60	1,010.38	-3.64%
EBITDA Margin	32.26%	33.21%		44.76%		32.90%	39.07%	
EBIT	253.71	607.81	-58.26%	447.63	-43.32%	861.53	904.57	-4.76%
EBIT Margin	26.40%	30.42%		39.97%		29.12%	34.98%	
Financing costs	5.91	10.68		9.36		16.59	22.06	
Taxes	68.40	209.41		121.05		277.81	269.82	
Net Profit after tax	179.41	387.73	-53.73%	317.23	-43.45%	567.13	612.69	-7.44%
NP Margin	18.67%	19.41%		28.33%		19.17%	23.69%	
EPS (basic & diluted not annualised)	1.41	3.05		2.49		4.47	4.82	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	55.61	55.08		53.40		110.69	105.32	
R&D expenses	123.87	159.89	-22.52%	116.61	6.23%	283.76	276.73	2.54%

14-Nov-18

2018-19 Q2 results

News Release



- During the period Suven secures 12 product patents covering Australia, Canada, China, Eurasia, Hong Kong, Israel, Japan, New Zealand, Sri Lanka and USA.
- Updates on CRAMS projects: Total – 116; Phase 1 – 76, Phase 2 – 35, Phase 3 – 1 and commercial – 4.
- Suven presented at 11th Clinical Trials on Alzheimer’s Disease (CTAD) held in October 2018 in Barcelona, Spain.
- Suven presented at Neurosciences 2018 held in November 2018 in San Diego, USA
- Suven completed enrollment of last patient (563rd) in SUVN-502, Phase 2, POC study conducted in USA. With this enrollment, we expect top-line data release by July/Aug, 2019.